MA
Highly rated in
16
conditions

Dr. Manmeet S. Ahluwalia

Geisinger Clinic
East Meadow, NY
Highly rated in
16
conditions
Specialties:Oncology | Hospital Medicine | Hematology Oncology
Experience:8 Years
Clinical Trials:Currently Recruiting for 7 Trials
Accepts:New PatientsMedicare
Highly rated in
16
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Manmeet S. Ahluwalia's experience treating your condition:
About Dr. Manmeet S. Ahluwalia

Manmeet Ahluwalia is an Oncologist and a Hospital Medicine expert in East Meadow, New York. Ahluwalia has been practicing medicine for over 8 years and is highly rated in 16 conditions, according to our data. His top areas of expertise are Brain Tumor, Astrocytoma, Glioblastoma, Glioma, and Gamma Knife Radiosurgery. He is licensed to treat patients in New York and Pennsylvania. Ahluwalia is currently accepting new patients.

His clinical research consists of co-authoring 196 peer reviewed articles and participating in 40 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Manmeet S. Ahluwalia it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Manmeet S. Ahluwalia accepts the following insurance:

  •  Ambetter
Locations
East Meadow, NY 11554
Background & Education
Graduate Institution
New York College Of Osteo Medicine Of New York Institute Of Technology, 2015
Specialties
Oncology
Hospital Medicine
Hematology Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
St Francis Hospital & Heart Center
Geisinger Medical Center Muncy
Geisinger Medical Center
Geisinger Bloomsburg Hospital
Geisinger Jersey Shore Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

38 Clinical Trials
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: TemozolomideLomustineRegorafenibPaxalisibVAL-083
Study Phase: Phase 2/Phase 3
A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Pivotal Study Assessing the Efficacy of Targeted Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin
Enrollment Status: Recruiting
Publish Date: November 07, 2022
Intervention Type: Device, Drug
Study Phase: Phase 3
A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma
Enrollment Status: Recruiting
Publish Date: November 07, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 Using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
Enrollment Status: Recruiting
Publish Date: October 26, 2022
Intervention Type: Device
Study Phase: Not Applicable
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Enrollment Status: Recruiting
Publish Date: August 25, 2022
Intervention Type: Biological
Study Drug: SurVaxM
Study Phase: Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Recruiting
Publish Date: June 23, 2022
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016Anti-PD-1Anti-CD137
Study Phase: Phase 1
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Drug
Study Drug: Regadenoson
Study Phase: Phase 1
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tkValacyclovirTemozolomideNivolumab
Study Phase: Phase 1
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Drug, Procedure
Study Drugs: BGB-290 PARP InhibitorTemozolomide
Study Phase: Phase 1/Phase 2
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Other, Drug
Study Drug: Terameprocol
Study Phase: Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Biological, Drug
Study Drugs: EncorafenibBinimetinib
Study Phase: Phase 2
Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer
Enrollment Status: Not yet recruiting
Publish Date: November 28, 2022
Intervention Type: Combination Product
Study Phase: Phase 1
Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)
Enrollment Status: Active, not recruiting
Publish Date: November 09, 2022
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 1
Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: November 01, 2022
Intervention Type: Drug, Radiation
Study Drugs: RuxolitinibTemozolomide
Study Phase: Phase 1
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: October 03, 2022
Intervention Type: Drug, Other, Radiation
Study Drug: BAL101553
Study Phase: Phase 1
Prospective Surgical Study on the Feasibility of Semi-Automated Tissue Collection, Stabilization, Preservation, and Site Transfer - Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue
Enrollment Status: Active, not recruiting
Publish Date: September 27, 2022
Intervention Type: Device
Study Phase: Not Applicable
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: September 21, 2022
Intervention Type: Biological, Other, Drug
Study Drugs: IpilimumabNivolumabTemozolomide
Study Phase: Phase 1
Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Enrollment Status: Active, not recruiting
Publish Date: August 26, 2022
Intervention Type: Drug
Study Drugs: PembrolizumabSurVaxMSargramostimMontanide ISA 51
Study Phase: Phase 2
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: August 26, 2022
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: July 14, 2022
Intervention Type: Drug, Radiation
Study Drugs: IbrutinibTemozolomide
Study Phase: Phase 1
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: March 31, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Montanide ISA 51 VGSargramostimSVN53-67/M57-KLH Peptide VaccineTemozolomide
Study Phase: Phase 2
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
Enrollment Status: Terminated
Publish Date: October 19, 2021
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Device, Drug
Study Phase: Phase 1
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: June 02, 2021
Intervention Type: Device, Drug
Study Phase: Phase 2
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Enrollment Status: Active, not recruiting
Publish Date: May 25, 2021
Intervention Type: Drug
Study Drugs: NivolumabBevacizumab
Study Phase: Phase 2
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: July 24, 2020
Intervention Type: Biological, Device, Other
Study Phase: Phase 2
Phase II Study of Radioimmunotherapy With Zevalin (Ibritumomab Tiuxetan) Therapy for Patients With Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)
Enrollment Status: Terminated
Publish Date: July 24, 2020
Intervention Type: Biological, Radiation
Study Phase: Phase 2
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Withdrawn
Publish Date: March 24, 2020
Intervention Type: Other, Device, Radiation, Biological, Drug, Procedure
Study Phase: Phase 2/Phase 3
Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)
Enrollment Status: Completed
Publish Date: December 12, 2017
Intervention Type: Other, Drug
Study Phase: Phase 2
View 31 Less Clinical Trials -
196 Total Publications
Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors.
Journal: Biomedicines
Published: July 19, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
AM
Dr. Alison J. Moskowitz
Hematology Oncology | Hematology | Oncology
Highly rated in
34
conditions
Hematology Oncology
Hematology
Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 21.2 mi

Alison Moskowitz is a Hematologist Oncology specialist and a Hematologist in New York, New York. Moskowitz has been practicing medicine for over 20 years and is highly rated in 34 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in New York. Moskowitz is currently accepting new patients.

RF
Richard R. Furman
Dr. Richard R. Furman
Oncology | Hematology Oncology | Hematology
Highly rated in
34
conditions
Oncology
Hematology Oncology
Hematology

NewYork-Presbyterian Healthcare System

Richard Silver

520 E 70th St, 
New York, NY 
 21.1 mi

Richard Furman is an Oncologist and a Hematologist Oncology expert in New York, New York. Furman has been practicing medicine for over 30 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in New York.

GR
Gail J. Roboz
Dr. Gail J. Roboz
Oncology | Hematology Oncology | Hematology
Highly rated in
40
conditions
Oncology
Hematology Oncology
Hematology

NewYork-Presbyterian Healthcare System

Cardiology At Weill Cornell Medical Center, Starr Pavilion

520 E 70th St, 
New York, NY 
 21.1 mi

Gail Roboz is an Oncologist and a Hematologist Oncology expert in New York, New York. Roboz has been practicing medicine for over 29 years and is highly rated in 40 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in New York.